Novavax Inc. (NVAX)
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc.'s Q4 2024 earnings — released yesterday — show a significant revenue decline and continued losses, despite cost-cutting measures and the deal with Sanofi, worth up to $1.2bn. The company's future hinges on the approval of its Biologics License Application this April, triggering a $175m milestone from Sanofi, and the success of its partnership with Sanofi, amidst regulatory uncertainties. Novavax aims to achieve profitability by 2027 through cost reductions and potential milestone payments from Sanofi's CIC vaccine launch, but the overall picture does not inspire too much confidence.
1 Biotech Stock to Buy in 2025, and 1 to Avoid
Viking Therapeutics (VKTX 3.06%) and Novavax (NVAX -3.55%) were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had exciting clinical progress, while the latter signed a lucrative deal with a biotech giant that had Wall Street cheering.
Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates
NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo Nordisk for $200 million.
Novavax, Inc. (NVAX) Q4 2024 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer Ruxandra Draghia-Akli - Executive Vice President, Head of Research and Development John Trizzino - President and Chief Operating Officer Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Robert Walker - Senior Vice President and Chief Medical Officer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank of America Securities Eric Joseph - JPMorgan Vernon Bernardino - H.C.
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
On Thursday, Novavax Inc NVAX reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the consensus of $84.35 million. The decrease was due to lower product sales under APA agreements.
Novavax (NVAX) Reports Q4 Loss, Tops Revenue Estimates
Novavax (NVAX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.44 per share a year ago.
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 vaccines, its only product on the market.
Novavax Stock Is Rising. Revenue Beat Estimates.
Fourth-quarter revenue came in at $88 million, above expectations of 84 million, while Novavax continues to shift away from Covid-19 vaccines.
Novavax (NVAX) Declines More Than Market: Some Information for Investors
Novavax (NVAX) closed the most recent trading day at $7.92, moving -1.25% from the previous trading session.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax to Report Q4 Earnings: Here's What You Can Expect
On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline.
